To drive Trophon EPR ultrasound disinfection product development
GE is investing US$7.5m in Australia-based Nanosonics, a developer of innovative technology for infection control, to progress the development and distribution of the Trophon EPR ultrasound transducer disinfecting system.
The investment is being made through the GE healthymagination Fund, which makes investments in healthcare technology companies.
GE Healthcare worked with Nanosonics in 2006 to support the validation of the Trophon EPR, which received US FDA approval in 2011. Trophon is now installed at more than 800 sites globally.
The advantages of the Trophon EPR system are:
Michael Ackland, president and ceo of GE Healthcare Australia and New Zealand, said: “Nanosonics has built an attractive business with an extraordinary product.
“We believe the continued collaboration with Nanosonics will help serve our healthcare customers better, complementing GE’s suite of ultrasound technologies, software and services. By expanding our sales footprint in Japan as well as in the existing locations such as the US, Canada and Europe, GE will help customers improve their overall quality in ultrasound processes.”